|
1
|
Druker BJ: Translation of the Philadelphia
chromosome into therapy for CML. Blood. 112:4808–4817. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jabbour E, Cortes J and Kantarjian H:
Long-term outcomes in the second-line treatment of chronic myeloid
leukemia: a review of tyrosine kinase inhibitors. Cancer.
117:897–906. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hochhaus A, O’Brien SG, Guilhot F, et al:
Six-year follow-up of patients receiving imatinib for the
first-line treatment of chronic myeloid leukemia. Leukemia.
23:1054–1061. 2009.PubMed/NCBI
|
|
4
|
de Lavallade H, Apperley JF, Khorashad JS,
et al: Imatinib for newly diagnosed patients with chronic myeloid
leukemia: incidence of sustained responses in an intention-to-treat
analysis. J Clin Oncol. 26:3358–3363. 2008.PubMed/NCBI
|
|
5
|
Marin D, Milojkovic D, Olavarria E, et al:
European LeukemiaNet criteria for failure or suboptimal response
reliably identify patients with CML in early chronic phase treated
with imatinib whose eventual outcome is poor. Blood. 112:4437–4444.
2008. View Article : Google Scholar
|
|
6
|
Baccarani M, Castagnetti F, Gugliotta G,
Palandri F and Soverini S: Response definitions and European
Leukemianet Management recommendations. Best Pract Res Clin
Haematol. 22:331–341. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Soverini S, Colarossi S, Gnani A, et al:
Contribution of ABL kinase domain mutations to imatinib resistance
in different subsets of Philadelphia-positive patients: by the
GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res.
12:7374–7379. 2006. View Article : Google Scholar
|
|
8
|
Larson RA, Druker BJ, Guilhot F, et al:
Imatinib pharmacokinetics and its correlation with response and
safety in chronic-phase chronic myeloid leukemia: a subanalysis of
the IRIS study. Blood. 111:4022–4028. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Picard S, Titier K, Etienne G, et al:
Trough imatinib plasma levels are associated with both cytogenetic
and molecular responses to standard-dose imatinib in chronic
myeloid leukemia. Blood. 109:3496–3499. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Thomas J, Wang L, Clark RE and Pirmohamed
M: Active transport of imatinib into and out of cells: implications
for drug resistance. Blood. 104:3739–3745. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
White DL, Saunders VA, Dang P, et al: Most
CML patients who have a suboptimal response to imatinib have low
OCT-1 activity: higher doses of imatinib may overcome the negative
impact of low OCT-1 activity. Blood. 110:4064–4072. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Clark RE, Davies A, Pirmohamed M and
Giannoudis A: Pharmacologic markers and predictors of responses to
imatinib therapy in patients with chronic myeloid leukemia. Leuk
Lymphoma. 49:639–642. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang L, Giannoudis A, Lane S, Williamson
P, Pirmohamed M and Clark R: Expression of the uptake drug
transporter hOCT1 is an important clinical determinant of the
response to imatinib in chronic myeloid leukemia. Clin Pharmacol
Ther. 83:258–264. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rodrigues AS, Dinis J, Gromicho M, Martins
C, Laires A and Rueff J: Genomics and cancer drug resistance. Curr
Pharm Biotechnol. 13:651–673. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cortez MAA, Scrideli CA, Yunes JA, et al:
mRNA expression profile of multidrug resistance genes in childhood
acute lymphoblastic leukemia. Low expression levels associated with
a higher risk of toxic death. Pediatr Blood Cancer. 53:996–1004.
2009. View Article : Google Scholar
|
|
16
|
Raaijmakers MHGP: ATP-binding-cassette
transporters in hematopoietic stem cells and their utility as
therapeutical targets in acute and chronic myeloid leukemia.
Leukemia. 21:2094–2102. 2007. View Article : Google Scholar
|
|
17
|
Steiner E, Holzmann K, Elbling L, Micksche
M and Berger W: Cellular functions of vaults and their involvement
in multidrug resistance. Curr Drug Targets. 7:923–934. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vasconcelos FC, Silva KL, Souza PSD, et
al: Variation of MDR protein expression and activity levels
according to clinical status and evolution of CML patients.
Cytometry B Clin Cytom. 80:158–166. 2010.PubMed/NCBI
|
|
19
|
Stromskaya T, Rybalkina EY, Kruglov S, et
al: Role of p-glycoprotein in evolution of populations of chronic
myeloid leukemia cells treated with imatinib. Biochemistry (Mosc).
73:29–37. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gromicho M, Dinis J, Magalhães M, et al:
Development of imatinib and dasatinib resistance: dynamics of
expression of drug transporters ABCB1, ABCC1, ABCG2, MVP, and
SLC22A1. Leuk Lymphoma. 52:1980–1990. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nijmeijer BA, Szuhai K, Goselink HM, et
al: Long-term culture of primary human lymphoblastic leukemia cells
in the absence of serum or hematopoietic growth factors. Exp
Hematol. 37:376–385. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
van Dongen JJ, Macintyre EA, Gabert JA, et
al: Standardized RT-PCR analysis of fusion gene transcripts from
chromosome aberrations in acute leukemia for detection of minimal
residual disease. Report of the BIOMED-1 Concerted Action:
investigation of minimal residual disease in acute leukemia.
Leukemia. 13:1901–1928. 1999.PubMed/NCBI
|
|
23
|
Gabert J, Beillard E, van der Velden VHJ,
et al: Standardization and quality control studies of ‘real-time’
quantitative reverse transcriptase polymerase chain reaction of
fusion gene transcripts for residual disease detection in leukemia
- a Europe Against Cancer program. Leukemia. 17:2318–2357.
2003.
|
|
24
|
Schefe JH, Lehmann KE, Buschmann IR, Unger
T and Funke-Kaiser H: Quantitative real-time RT-PCR data analysis:
current concepts and the novel ‘gene expression’s CT difference’
formula. J Mol Med. 84:901–910. 2006.PubMed/NCBI
|
|
25
|
Crossman LC, Druker BJ, Deininger MWN,
Pirmohamed M, Wang L and Clark RE: hOCT 1 and resistance to
imatinib. Blood. 106:1133–1134. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Burger H, van Tol H, Brok M, et al:
Chronic imatinib mesylate exposure leads to reduced intracellular
drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1)
drug transport pumps. Cancer Biol Therapy. 4:747–752. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gardner ER, Sparreboom A, Verweij J and
Figg WD: Lack of ABC transporter autoinduction in mice following
long-term exposure to imatinib. Cancer Biol Therapy. 7:412–415.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gurney H, Wong M, Balleine RL, et al:
Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype.
Clin Pharm Ther. 82:33–40. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xu C, Li CY-T and Kong A-NT: Induction of
phase I, II and III drug metabolism/transport by xenobiotics. Arch
Pharm Res. 28:249–268. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Eechoute K, Sparreboom A, Burger H, et al:
Drug transporters and imatinib treatment: implications for clinical
practice. Clin Cancer Res. 17:406–415. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
White DL, Saunders VA, Dang P, et al:
OCT-1-mediated influx is a key determinant of the intracellular
uptake of imatinib but not nilotinib (AMN107): reduced OCT-1
activity is the cause of low in vitro sensitivity to imatinib.
Blood. 108:697–704. 2006. View Article : Google Scholar
|
|
32
|
de Grouw EPLM, Raaijmakers MHGP, Boezeman
JB, et al: Preferential expression of a high number of ATP binding
cassette transporters in both normal and leukemic
CD34+CD38- cells. Leukemia. 20:750–754.
2006.PubMed/NCBI
|
|
33
|
de Lavallade H, Finetti P, Carbuccia N, et
al: A gene expression signature of primary resistance to imatinib
in chronic myeloid leukemia. Leukemia Res. 34:254–257.
2010.PubMed/NCBI
|
|
34
|
Villuendas R, Steegmann JL, Pollán M, et
al: Identification of genes involved in imatinib resistance in CML:
a gene-expression profiling approach. Leukemia. 20:1047–1054. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lange T, Günther C, Köhler T, et al: High
levels of BAX, low levels of MRP-1, and high platelets are
independent predictors of response to imatinib in myeloid blast
crisis of CML. Blood. 101:2152–2155. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Czyzewski K and Styczynski J: Imatinib is
a substrate for various multidrug resistance proteins. Neoplasma.
56:202–207. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shukla S, Sauna ZE and Ambudkar SV:
Evidence for the interaction of imatinib at the transport-substrate
site(s) of the multidrug-resistance-linked ABC drug transporters
ABCB1 (P-glycoprotein) and ABCG2. Leukemia. 22:445–447. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Scheffer GL, Schroeijers AB, Izquierdo MA,
Wiemer EA and Scheper RJ: Lung resistance-related protein/major
vault protein and vaults in multidrug-resistant cancer. Curr Opin
Oncol. 12:550–556. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
White DL, Dang P, Engler J, et al:
Functional activity of the OCT-1 protein is predictive of long-term
outcome in patients with chronic-phase chronic myeloid leukemia
treated with imatinib. J Clin Oncol. 28:2761–2767. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Engler JR, Frede A, Saunders VA,
Zannettino ACW, Hughes TP and White DL: Chronic myeloid leukemia
CD34+ cells have reduced uptake of imatinib due to low
OCT-1 activity. Leukemia. 24:765–770. 2010.PubMed/NCBI
|
|
41
|
Hu S, Franke RM, Filipski KK, et al:
Interaction of imatinib with human organic ion carriers. Clin
Cancer Res. 14:3141–3148. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
O’Hare T, Eide CA and Deininger MWN:
Bcr-Abl kinase domain mutations, drug resistance, and the road to a
cure for chronic myeloid leukemia. Blood. 110:2242–2249.
2007.PubMed/NCBI
|
|
43
|
Redaelli S, Piazza R, Rostagno R, et al:
Activity of bosutinib, dasatinib, and nilotinib against 18
imatinib-resistant BCR/ABL mutants. J Clin Oncol. 27:469–471. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wang L, Knight K, Lucas C and Clark RE:
The role of serial BCR-ABL transcript monitoring in predicting the
emergence of BCR-ABL kinase mutations in imatinib-treated patients
with chronic myeloid leukemia. Haematologica. 91:235–239.
2006.PubMed/NCBI
|
|
45
|
Gruber FX, Lundán T, Goll R, et al:
BCR-ABL isoforms associated with intrinsic or acquired resistance
to imatinib: more heterogeneous than just ABL kinase domain point
mutations? Med Oncol. 29:219–226. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Guilhot F, Apperley J, Kim D-W, et al:
Dasatinib induces significant hematologic and cytogenetic responses
in patients with imatinib-resistant or -intolerant chronic myeloid
leukemia in accelerated phase. Blood. 109:4143–4150. 2007.
View Article : Google Scholar
|
|
47
|
Ernst T, Hoffmann J, Erben P, et al: ABL
single nucleotide polymorphisms may masquerade as BCR-ABL mutations
associated with resistance to tyrosine kinase inhibitors in
patients with chronic myeloid leukemia. Haematologica.
93:1389–1393. 2008. View Article : Google Scholar
|
|
48
|
Willis SG, Lange T, Demehri S, et al:
High-sensitivity detection of BCR-ABL kinase domain mutations in
imatinib-naive patients: correlation with clonal cytogenetic
evolution but not response to therapy. Blood. 106:2128–2137. 2005.
View Article : Google Scholar
|
|
49
|
Jones D, Chen SS, Jabbour E, Rios MB,
Kantarjian H and Cortes J: Uncommon BCR-ABL kinase domain mutations
in kinase inhibitor-resistant chronic myelogenous leukemia and
Ph+ acute lymphoblastic leukemia show high rates of
regression, suggesting weak selective effects. Blood.
115:5428–5429. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Soverini S, Hochhaus A, Nicolini FE, et
al: Bcr-Abl kinase domain mutation analysis in chronic myeloid
leukemia patients treated with tyrosine kinase inhibitors:
recommendations from an expert panel on behalf of European
LeukemiaNet. Blood. 118:1208–1215. 2011. View Article : Google Scholar
|
|
51
|
Sharma P, Kumar L, Mohanty S and
Kochupillai V: Response to imatinib mesylate in chronic myeloid
leukemia patients with variant BCR-ABL fusion transcripts. Ann
Hematol. 89:241–247. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Polampalli S, Choughule A, Negi N, et al:
Analysis and comparison of clinicohematological parameters and
molecular and cytogenetic response of two Bcr/Abl fusion
transcripts. Genetics Mol Res. 7:1138–1149. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Lucas CM, Harris RJ, Giannoudis A, et al:
Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion
transcript have inferior responses to imatinib compared to patients
with the e14a2 transcript. Haematologica. 94:1362–1367. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Verma D, Kantarjian HM, Jones D, et al:
Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of
characteristics, outcomes, and prognostic significance. Blood.
114:2232–2235. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Dulucq S, Bouchet S, Turcq B, et al:
Multidrug resistance gene (MDR1) polymorphisms are associated with
major molecular responses to standard-dose imatinib in chronic
myeloid leukemia. Blood. 112:2024–2027. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Ni L-N, Li J-Y, Miao K-R, et al: Multidrug
resistance gene (MDR1) polymorphisms correlate with imatinib
response in chronic myeloid leukemia. Med Oncol. 28:265–269. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Kim DHD, Sriharsha L, Xu W, et al:
Clinical relevance of a pharmacogenetic approach using multiple
candidate genes to predict response and resistance to imatinib
therapy in chronic myeloid leukemia. Clin Cancer Res. 15:4750–4758.
2009. View Article : Google Scholar : PubMed/NCBI
|
